NCT02658097View on ClinicalTrials.gov

Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

February 26, 2022

Study Completion Date

March 10, 2023

Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab

200mg Pembrolizumab by IV infusion

RADIATION

Single Fraction Radiation Therapy

8Gy radiation therapy will be given in a single fraction on the first day of treatment

Trial Locations (1)

44118

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT02658097 - Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | Biotech Hunter | Biotech Hunter